

Home > MycoSynVac: synthetic biology, paying attention to ethical issues



Thursday, September 22, 2016 - 09:11 **Target** Industry & Commerce [1] **Topic** Microbiology [2] Stakeholders [3] Vaccination [4] **Tags** Vaccine [5] <u>ethics [6]</u> synthetic biology [7]

Vaccines have had broad medical impact, but existing vaccine technologies and production methods are limited in their ability to respond to certain pathogens. Other hurdles are due to difficulties in large scale production. <u>MycoSynVac</u> [8] project proposes a new way for developing vaccines, by using of cuttingedge synthetic biology methodologies to engineer *Mycoplasma pneumoniae* as a universal chassis for vaccination.

Mycoplasmas are resistant to many of the common antibiotics due to their lack of cell wall. They have a wide variety of hosts, including humans, mammals, reptiles, fish, arthropods and plants. Every year, infections caused by Mycoplasmas in poultry, cows, and pigs, result in multimillion euros losses in USA and Europe.

M. pneumoniae is an ideal starting point for designing such a vaccine chassis due to its small genome (860 kb) and because it is probably the organism with the most comprehensive systems biology data acquired so far. By genome comparison, metabolic modeling and rationally engineering its genome, we will create a vaccine chassis that will be introduced into an industrial pipeline. The final results should provide a cheap and fast production process and a universal Mycoplasma chassis that could be used in a pipeline to vaccinate against Mycoplasma species, as well as any pathogen. In a first stage vaccine will face veterinary infections (i.e. pigs and cattle), but in the future they may also be used in human health.

The partners, aware of the concern that

synthetic biology raises, are very sensitive to project ethical implications and maintain a continuous dialogue with public opinion, including the general public, scientists and policy makers. As an example, we are organizing some Science Cafés in order to explain the main advantages of synthetic biology applied to vaccines. So far, two of them have been organized, one in <u>Barcelona</u> [9] and one in <u>Amsterdam</u> [10].

It is expected that by year 2020, we will be able to produce a serum (animal) free vaccine, at a reduced cost and with an improved protection profile (hopefully one shot protection). Stay tuned at <u>www.mycosynvac.eu</u> [11].

Newsletters

Select the newsletter(s) to which you want to subscribe or unsubscribe.

News from Asset project Responsible Research and Innovation Newsletter Asset PPRB

E-mail *

Contacts

Facebook

Twitter

YouTube

<u>LinkedIn</u>

Contacts

General inquiries: info@asset-scienceinsociety.eu

ASSET

Action plan on Science in Society related issues in Epidemics and Total pandemics European Commission

This project has received funding from the European Union?s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 612236.

Source URL: http://www.asset-scienceinsociety.eu/news/features/mycosynvac-synthetic-biology-paying-attention-ethical-issues

Links

[1] http://www.asset-scienceinsociety.eu/target/industry-commerce

[2] http://www.asset-scienceinsociety.eu/topic/microbiology

[3] http://www.asset-scienceinsociety.eu/topic/stakeholders

[4] http://www.asset-scienceinsociety.eu/topic/vaccination

[5] http://www.asset-scienceinsociety.eu/tags/vaccine

[6] http://www.asset-scienceinsociety.eu/tags/ethics

[7] http://www.asset-scienceinsociety.eu/tags/synthetic-biology

[8] http://www.mycosynvac.eu/

[9] http://www.mycosynvac.eu/2015/09/prbb-open-day-invitation-to-attend-the-mycosynvac-and-prbb-science-cafe/

[10] http://www.mycosynvac.eu/2016/06/science-cafe-synbio-vaccine-engineering-and-its-societalimplications/

[11] file:///C:/Users/Roberta/hubiC/Documents/progetti%20europei/asset/www.mycosynvac.eu